Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection

c‐MET is implicated in the pathogenesis and growth of a wide variety of human malignancies, including colorectal cancer (CRC). The aim of the present study was to clarify the association between c‐MET expression and tumor recurrence in CRC patients after curative liver resection, and to evaluate concordance in c‐MET expression and various mutations of KRAS, BRAF and PIK3CA between primary CRC and paired liver metastases. A cohort of patients was tested for c‐MET immunoreactivity (i.e. immunohistochemistry [IHC]) and KRAS, BRAF and PIK3CA mutations. Analyses were performed both on primary tumors and paired liver metastases, and the association between IHC and mutations results were assessed. A total of 108 patients were eligible. A total of 53% of patients underwent simultaneous resection of primary tumors and metastases, and the others underwent metachronous resection. Levels of concordance between primary tumors and metastases were 65.7%, 87.7%, 100% and 95.2% for c‐MET, KRAS, BRAF and PIK3CA, respectively. High levels of c‐MET expression (c‐MET‐high) in the primary tumors were observed in 52% of patients. Relapse‐free survival was significantly shorter for patients with c‐MET‐high primary tumors (9.7 months) than for those with c‐MET‐low primary tumors (21.1 months) (P = 0.013). These results suggest that a high level of genetic concordance in KRAS, BRAF and PIK3CA between primary tumors and liver metastases, and c‐MET‐high in the primary tumors were associated with shorter relapse‐free survival after hepatic metastasectomy.

[1]  M. Dieci,et al.  Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Christophi,et al.  Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met , 2013, Clinical & Experimental Metastasis.

[3]  O. Ogunwobi,et al.  Epigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma , 2013, PloS one.

[4]  M. Tzardi,et al.  Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer , 2013, Modern Pathology.

[5]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Ge,et al.  Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer: A Systematic Review and Meta-analysis , 2012, Diseases of the colon and rectum.

[7]  J. Tabernero,et al.  Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials , 2012, Molecular Cancer Therapeutics.

[8]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[9]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[10]  H. Tomita,et al.  Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. , 2010, International journal of oncology.

[11]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[12]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[13]  H. Müller-Hermelink,et al.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy , 2010, Journal of oncology.

[14]  A. Filho,et al.  MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. , 2009, Anticancer research.

[15]  G. Fontanini,et al.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.

[16]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[17]  E. Fisher,et al.  Survival after hepatic resection of colorectal cancer metastases , 2009, Cancer.

[18]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  I. Floriani,et al.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.

[20]  R. Palmqvist,et al.  c-Met expression in primary tumors and their corresponding distant metastases. , 2008, Molecular medicine reports.

[21]  F. Barany,et al.  c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. , 2008, Cancer letters.

[22]  P. Jänne,et al.  Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.

[23]  M. Gonen,et al.  Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases , 2006, Annals of Surgical Oncology.

[24]  A. Makris,et al.  Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer , 2004, British Journal of Cancer.

[25]  Roderick Turner,et al.  c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[27]  C. Köhne,et al.  Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[29]  F. Schmitz,et al.  Functional Expression of HGF and Its Receptor in Human Colorectal Cancer , 2000, Digestion.

[30]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[32]  C. Cooper,et al.  Tyrosine kinase receptor indistinguishable from the c-met protein , 1989, Nature.